phenylalanine has been researched along with lx1032 in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 8 (29.63) | 2.80 |
| Authors | Studies |
|---|---|
| Barriuso, J; Hubner, RA; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Anthony, LB; Banks, P; Bergsland, E; Caplin, ME; Fleming, D; Grande, E; Hörsch, D; Jackson, S; Kulke, MH; Kunz, PL; Lapuerta, P; Lombard-Bohas, C; Öberg, K; Pavel, M; Sands, AT; Valle, JW; Warner, RR; Welin, S; Zambrowicz, B | 1 |
| Kulke, MH | 1 |
| Frech, F; Joish, VN; Lapuerta, P | 2 |
| Masab, M; Saif, MW | 1 |
| Anthony, L; Arnold, K; Bergsland, E; Caplin, M; DiBenedetti, DB; Ervin, C; Evans, E; Hörsch, D; Jackson, S; Kulke, MH; Kunz, P; Lapuerta, P; Law, L; Metz, DC; Öberg, K; Pasieka, J; Pavel, M; Pavlakis, N; Ramage, J; Yang, QM | 1 |
| Kasi, PM | 2 |
| Anthony, LB; Benavent, M; Fleming, D; Fleming, R; Garcia-Carbonero, R; Gross, DJ; Hörsch, D; Jiang, W; Kassler-Taub, K; Kulke, MH; Kunz, PL; Lapuerta, P; Pavel, M; Perros, P; Srirajaskanthan, R; Warner, RRP; Wason, S; Weickert, MO | 1 |
| Chandrasekharan, C; Dillon, JS | 1 |
| Anthony, LB; Bergsland, E; Caplin, ME; Grande, E; Hörsch, D; Kaltsas, G; Kittur, A; Kulke, MH; Kunz, PL; Lapuerta, P; Lombard-Bohas, C; Öberg, K; Pavel, M; Ramage, JK; Valle, JW; Weickert, MO; Welin, S; Yang, QM | 1 |
| Lyseng-Williamson, KA | 1 |
| Jiang, W; Lapuerta, P; Perez-Olle, R | 1 |
| Beaumont, JL; Cella, D; Feuilly, M; Hörsch, D; Houchard, A; Hudgens, S; Kulke, MH; Lapuerta, P; Marteau, F; Pavel, M; Ramage, J | 1 |
| Anthony, LB; Bergsland, E; Caplin, ME; Dillon, JS; Hörsch, D; Jiang, W; Kassler-Taub, K; Kulke, MH; Lapuerta, P; O'Dorisio, TM; Öberg, K; Pavel, M; Warner, RRP | 1 |
| Benson Iii, AB; Wolin, EM | 1 |
| Benson, AB; Dharba, S; Fish-Steagall, A; Giacalone, S; Joish, VN; Kapoor, K; Lapuerta, P; Perez-Olle, R; Strosberg, J | 1 |
| Castaño, JP; de Herder, WW; Dogan-Oruc, F; Feelders, RA; Herrera-Martínez, AD; Hofland, LJ; Van den Dungen, R; van Koetsveld, PM | 1 |
| Bader, M | 1 |
| Benson, AB; Dharba, S; Joish, VN; Lapuerta, P; Sapre, D; Strosberg, J | 1 |
| Anthony, LB; Banks, P; Bergsland, E; Dillon, JS; Hörsch, D; Kulke, MH; Kunz, PL; Lapuerta, P; McKee, C; O'Dorisio, TM; Pavel, M; Warner, RRP; Welin, S | 1 |
| Feuilly, M; Fust, K; Kohli, M; Marteau, F; Maschio, M; Myrenfors, P; Pritchard, DM; Singh, S | 1 |
| Hota, S; Srirajaskanthan, R | 1 |
| Anthony, L; Banks, P; Benavent, M; Bergsland, E; Binder, P; Caplin, M; Gross, DJ; Hörsch, D; Kassler-Taub, KB; Kulke, MH; Lapuerta, P; Öberg, K; Pavel, M; Valle, JW; Welin, S | 1 |
| Clement, D; Houchard, A; Keeber, L; Kulke, M; Pavel, M; Srirajaskanthan, R; Weickert, MO | 1 |
6 review(s) available for phenylalanine and lx1032
| Article | Year |
|---|---|
Telotristat ethyl: a new option for the management of carcinoid syndrome.
Topics: Animals; Carcinoid Tumor; Clinical Trials as Topic; Humans; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines; Somatostatin; Tryptophan Hydroxylase | 2016 |
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Topics: Administration, Oral; Diarrhea; Female; Humans; Male; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines | 2017 |
Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea.
Topics: Diarrhea; Drug Interactions; Drug Therapy, Combination; Humans; Malignant Carcinoid Syndrome; Phenylalanine; Pyrimidines; Randomized Controlled Trials as Topic; Signal Transduction; Somatostatin; Treatment Outcome; Tryptophan Hydroxylase | 2018 |
Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.
Topics: Clinical Trials as Topic; Diarrhea; Humans; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines; Somatostatin | 2018 |
Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Male; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Practice Guidelines as Topic; Prospective Studies; Pyrimidines; Quality of Life; Somatostatin; Treatment Outcome | 2019 |
Inhibition of serotonin synthesis: A novel therapeutic paradigm.
Topics: Animals; Brain; Drug Development; Enzyme Inhibitors; Humans; Isoenzymes; Mental Disorders; Phenylalanine; Pyrimidines; Serotonin; Tryptophan Hydroxylase | 2020 |
8 trial(s) available for phenylalanine and lx1032
| Article | Year |
|---|---|
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Topics: Aged; Antineoplastic Agents, Hormonal; Defecation; Diarrhea; Double-Blind Method; Female; gamma-Glutamyltransferase; Gastrointestinal Agents; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Middle Aged; Nausea; Octreotide; Peptides, Cyclic; Phenylalanine; Pyrimidines; Somatostatin; Tryptophan Hydroxylase | 2017 |
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
Topics: Diarrhea; Double-Blind Method; Female; Humans; Male; Malignant Carcinoid Syndrome; Middle Aged; Phenylalanine; Pyrimidines; Treatment Outcome | 2017 |
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Diarrhea; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Middle Aged; Phenylalanine; Pyrimidines; Somatostatin; Treatment Outcome | 2018 |
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Topics: Aged; Body Weight; Diarrhea; Double-Blind Method; Female; Humans; Male; Malignant Carcinoid Syndrome; Middle Aged; Phenylalanine; Pyrimidines; Treatment Outcome; Tryptophan Hydroxylase | 2018 |
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.
Topics: Aged; Diarrhea; Double-Blind Method; Female; Humans; Male; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Phenylalanine; Pyrimidines; Quality of Life; Treatment Outcome; Tryptophan Hydroxylase | 2018 |
TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Topics: Aged; Cohort Studies; Diarrhea; Female; Follow-Up Studies; Humans; International Agencies; Male; Malignant Carcinoid Syndrome; Patient Reported Outcome Measures; Phenylalanine; Prognosis; Pyrimidines | 2019 |
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
Topics: Adult; Clinical Trials, Phase III as Topic; Defecation; Double-Blind Method; Female; Gastrointestinal Motility; Humans; Male; Malignant Carcinoid Syndrome; Middle Aged; Phenylalanine; Placebos; Pyrimidines; Severity of Illness Index; Time Factors; Treatment Outcome | 2021 |
Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST.
Topics: Body Weight Maintenance; Humans; Malignant Carcinoid Syndrome; Phenylalanine; Pyrimidines; Quality of Life; Treatment Outcome; Weight Loss | 2021 |
13 other study(ies) available for phenylalanine and lx1032
| Article | Year |
|---|---|
Advances in the management of patients with carcinoid syndrome.
Topics: Carcinoid Tumor; Clinical Trials, Phase III as Topic; Diarrhea; Humans; Malignant Carcinoid Syndrome; Phenylalanine; Pyrimidines | 2017 |
Telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea.
Topics: Antidiarrheals; Diarrhea; Drug Therapy, Combination; Humans; Malignant Carcinoid Syndrome; Octreotide; Phenylalanine; Pyrimidines; Treatment Outcome | 2017 |
Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.
Topics: Adult; Aged; Cost-Benefit Analysis; Diarrhea; Drug Costs; Drug Therapy, Combination; Female; Health Resources; Humans; Male; Malignant Carcinoid Syndrome; Markov Chains; Middle Aged; Phenylalanine; Pyrimidines; Quality-Adjusted Life Years; Somatostatin; Treatment Outcome; United States | 2018 |
Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
Topics: Antidiarrheals; Budgets; Diarrhea; Health Care Costs; Humans; Insurance, Health; Malignant Carcinoid Syndrome; Models, Economic; Phenylalanine; Pyrimidines; Somatostatin; United States | 2017 |
Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension.
Topics: Aged; Chest Pain; Female; Humans; Hypertension; Male; Malignant Carcinoid Syndrome; Middle Aged; Phenylalanine; Pyrimidines | 2018 |
Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.
Topics: Diarrhea; Humans; Malignant Carcinoid Syndrome; Phenylalanine; Prevalence; Pyrimidines; Quality of Life; Somatostatin; Treatment Outcome; Tryptophan Hydroxylase | 2018 |
In Reply: Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension.
Topics: Chest Pain; Humans; Hypertension; Malignant Carcinoid Syndrome; Phenylalanine; Pyrimidines | 2018 |
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Female; Humans; Male; Malignant Carcinoid Syndrome; Middle Aged; Patient Safety; Phenylalanine; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2019 |
Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; In Vitro Techniques; Neuroendocrine Tumors; Pancreatic Neoplasms; Phenylalanine; Pyrimidines; Serotonin; Tryptophan Hydroxylase; Tumor Cells, Cultured | 2020 |
Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Child; Child, Preschool; Defecation; Diarrhea; Female; Flushing; Humans; Infant; Infant, Newborn; Male; Malignant Carcinoid Syndrome; Middle Aged; Nausea; Patient Reported Outcome Measures; Phenylalanine; Pyrimidines; Recovery of Function; Time Factors; Treatment Outcome; Young Adult | 2020 |
A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.
Topics: Budgets; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Malignant Carcinoid Syndrome; Markov Chains; Middle Aged; Models, Economic; Phenylalanine; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Somatostatin; Standard of Care; Sweden | 2020 |
Regarding "TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World".
Topics: Humans; Malignant Carcinoid Syndrome; Patient Reported Outcome Measures; Phenylalanine; Pyrimidines | 2020 |
Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
Topics: Adult; Humans; Malignant Carcinoid Syndrome; Phenylalanine; Pyrimidines; Quality of Life; Treatment Outcome | 2022 |